Skip to main content
Everything PR News
EPR

Pharma PR and Marketing: News, Guides and Case Studies

everything-pr.com/pharma

Drug approvals, clinical trials, patient advocacy and the agencies behind pharma and biotech communications.

Pharma PR and marketing earns trust for medicines, the companies that make them and the patients who use them, under FDA promotion rules. GLP-1 makers and telehealth sellers spent more than $1.1 billion on national TV ads in 2025, per iSpot.tv data. This hub covers ad rules, campaigns, agencies and AI visibility.

9 articles in this category·By EPR Editorial Team· Read the guide
EPR Pharma PR and Marketing: News, Guides and Case Studies: How medicines, biotech companies and drugmakers earn trust through PR, marketing and AI answers. | Everything-PR industry coverage
Full Archive

All articles in Pharma PR and Marketing: News, Guides and Case Studies

9 articles
The Guide

Inside Pharma PR and Marketing: News, Guides and Case Studies: market, players, and the questions we get asked

By EPR Editorial Team·Industry briefing

Pharma PR and marketing is the work of earning trust for medicines, the companies that make them and the patients who use them. It combines earned media, advertising, patient education and regulator-safe messaging. The category is led by brands such as Eli Lilly and Novo Nordisk, and by the healthcare PR firms ranked in EPR’s 20 best healthcare PR agencies. GLP-1 drug makers and telehealth sellers spent more than $1.1 billion on national TV ads in 2025, nearly one-fifth of all pharma linear TV spending, according to iSpot.tv data provided to eMarketer. This hub collects EPR’s pharma guides, campaign lists, case studies and AI visibility research. It describes marketing, not medical guidance.

Key facts

  • More than $1.1 billion: GLP-1 national TV ad spend in 2025 (iSpot.tv via eMarketer)
  • Sept 9, 2025: FDA announced a crackdown on misleading drug advertising and sent thousands of letters to drug companies
  • About $8 billion: pharma direct-to-consumer ad spend cited in EPR’s AI citation research
  • 5 AI engines tracked: ChatGPT, Claude, Perplexity, Gemini and Google AI Overviews

What does pharma PR and marketing cover?

Pharma PR and marketing covers five jobs, and each one runs under different rules. The table shows who is involved and what the work is for.

Segment Who is involved Main rules Typical goal
Prescription brand promotion Brand teams, ad agencies, PR firms FDA promotion rules, fair balance Awareness and appropriate use
Biotech and clinical-stage companies Founders, investor relations, PR firms SEC disclosure, FDA review Credibility with investors and clinicians
Corporate reputation Communications and policy teams Securities and public affairs rules Trust in the company
Patient education and advocacy Patient groups, brand and medical teams FDA and FTC claim rules Informed patients
Pricing and access Communications, government affairs Federal and state policy Clear access information

For the agency side, see EPR’s biotech PR guide and the healthcare PR agency ranking.

How is pharma advertising regulated now?

The FDA raised the bar for drug advertising on September 9, 2025. The agency announced what it called a crackdown on misleading direct-to-consumer ads, sent templated letters that it described as going to thousands of drug companies, and issued about 100 cease-and-desist letters aimed at specific products. A law firm tally of the 61 enforcement letters posted from September counted 8 warning letters and 53 untitled letters, and 38 of them targeted DTC television ads. Legal commentators also note that the FDA signaled a return to hundreds of letters a year, up from 10 to 20 untitled letters annually.

Teams that built clear, balanced creative before the announcement are best placed. A practical sequence:

  1. Review live ads and social posts against the current risk-disclosure expectations.
  2. Pull influencer and creator posts into the same review process.
  3. Keep one approved claims library that PR, brand and agency teams all use.
  4. Log every change with a date so the record is easy to show.

How much is GLP-1 marketing shaping the category?

GLP-1 medicines are the most visible marketing story in pharma. Beyond the $1.1 billion in 2025 TV spend, IQVIA data shared by a Wall Street analyst showed Zepbound prescriptions passing Wegovy in 2025, which gave Eli Lilly about 60% of the U.S. weight-loss drug market, as summarized in EPR’s 25 GLP-1 marketing campaigns and moves. Novo Nordisk and Lilly each reached a pricing agreement with the administration in November 2025, according to Fierce Pharma. A 2024 BMJ news report counted a 700% rise over four years in U.S. patients without diabetes starting GLP-1 treatment (Mahase, BMJ 2024), which helps explain why wellness marketers now treat these medicines as a starting assumption.

Which pharma brands do AI engines cite most?

Eli Lilly and Novo Nordisk lead in AI answers. EPR’s coverage of the AI Visibility Index from 5W Public Relations, a PR, creative and GEO agency, ranks the top 25 drugmakers by citation share across ChatGPT, Claude, Perplexity, Gemini and Google AI Overviews. Pharma spends about $8 billion a year on direct-to-consumer ads, yet the engines still cited Eli Lilly most often. Merck makes the world’s top-selling drug and ranks fifth. The full study is in Pharma Spent $8 Billion on TV. The Chatbox Cited Eli Lilly Anyway.

What is changing in pharma communications?

Five shifts are changing how drugmakers plan and defend their communications.

Direct-to-consumer pricing is now a marketing channel

Direct-to-consumer pricing now sits next to advertising and PR as a way to reach patients. Brand and communications teams explain price and access in plain language alongside the creative.

Enforcement raises the bar on claims and influencer posts

Commentators note the FDA has issued untitled letters over influencer posts that miss fair balance rules. Creator programs now need the same review as any other ad.

AI answers shape the first impression

Patients, reporters and investors ask answer engines about a medicine before they read a press release. Clear first-party facts and strong earned coverage give those engines good sources to cite.

Manufacturing and access stories carry the narrative

Eli Lilly’s U.S. manufacturing buildout of more than $20 billion shows how supply and investment stories support a brand’s reputation, as covered in EPR’s pharma research.

Category leaders defend their position

Leading brands now manage a citation environment as well as a media environment. Tracking which sources the engines cite helps leaders keep their facts accurate over time.

What works in pharma PR and marketing now?

Programs hold up when claims are clear, sources are public and the response plan exists before it is needed. The table lists the moves that matter most.

Play Action Why it works
Build one claims library Approve claims once and reuse them across PR, brand and agencies Consistent claims are easier to defend
Review creator content Apply fair-balance review to influencer posts Creator posts are part of the record
Publish first-party facts Put pricing, access and safety facts on the company site Engines and reporters cite primary sources
Track AI citations Check the five engines monthly for brand and product questions Early view of what patients read
Plan the crisis response Draft holding statements and a recall protocol in advance A fast, calm response protects trust

The 1982 Tylenol response remains the reference case for a calm, patient-first crisis reply. EPR covers it in Tylenol Crisis History.

Which pharma stories should you read first?

Everything-PR News, LLC and 5W Public Relations share a common ownership group. Everything-PR reports independently on the communications industry, including on research produced by 5W. Editorial decisions are made by Everything-PR's editorial team.

Frequently asked questions

What is pharma PR?

▾
Pharma PR is the communications work that builds trust for medicines and drug companies through earned media, patient education, advocacy and regulator-safe messaging.

How is pharma PR different from healthcare PR?

▾
Healthcare PR covers hospitals, insurers, providers and health tech. Pharma PR centers on prescription products, clinical evidence and FDA promotion rules.

What did the FDA do on September 9, 2025?

▾
The FDA announced a crackdown on misleading drug ads, sent templated letters it described as going to thousands of companies, and issued about 100 cease-and-desist letters about specific products.

How much did GLP-1 makers spend on TV in 2025?

▾
GLP-1 drug makers and telehealth sellers spent more than $1.1 billion on national TV ads, nearly one-fifth of pharma linear TV spending, per iSpot.tv data provided to eMarketer.

Which pharma companies do AI engines cite most?

▾
Eli Lilly and Novo Nordisk lead the 5W AI Visibility Index of the top 25 drugmakers, and Merck ranks fifth.

Can pharma brands work with influencers?

▾
Yes, with review. The FDA has issued untitled letters about influencer posts that missed fair balance rules, so creator content needs the same approval path as other ads.

How do I choose a pharma PR agency?

▾
Ask which products and regulators the team has worked with, who reviews claims, and how results are reported. EPR’s healthcare PR ranking lists 20 firms with shortlists for biotech, life sciences and pharma.

How much does pharma PR cost?

▾
It depends on scope, regulatory review and the number of products, and EPR's PR cost guide explains the pricing models.